Spots Global Cancer Trial Database for Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer
Official Title: Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer
Study ID: NCT03180437
Conditions
Study Description
Brief Summary: In this study, effects of γδT cells on human Pancreatic Cancer in combination with tumor reducing surgery, for example IRE going to be investigated.
Detailed Description: Pancreatic tumor will be removed using tumor reducing surgery such as IRE. PBMC of the healthy donor will be separated from peripheral blood. After making them potential cancer killer γδ T Cell, they will be infused to the patients as an immunotherapy treatment.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Biotherapy center in Fuda cancer hospital, Guangzhou, Guangdong, China
Contact Details
Name: Jibing Chen, PhD
Affiliation: Biological treatment center in Fuda cancer hospital Guangzhou
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
